LV12575B - Erythropoietin analogs - Google Patents

Erythropoietin analogs Download PDF

Info

Publication number
LV12575B
LV12575B LVP-00-60A LV000060A LV12575B LV 12575 B LV12575 B LV 12575B LV 000060 A LV000060 A LV 000060A LV 12575 B LV12575 B LV 12575B
Authority
LV
Latvia
Prior art keywords
epo
analogs
erythropoietin
analog
human
Prior art date
Application number
LVP-00-60A
Other languages
English (en)
Latvian (lv)
Other versions
LV12575A (en
Inventor
Thomas Edward Byrne
Steven George Elliott
Original Assignee
Kirin-Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23670537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12575(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin-Amgen Inc. filed Critical Kirin-Amgen Inc.
Publication of LV12575A publication Critical patent/LV12575A/xx
Publication of LV12575B publication Critical patent/LV12575B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LVP-00-60A 1989-10-13 2000-05-04 Erythropoietin analogs LV12575B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42144489A 1989-10-13 1989-10-13
PCT/US1990/005758 WO1991005867A1 (en) 1989-10-13 1990-10-09 Erythropoietin isoforms

Publications (2)

Publication Number Publication Date
LV12575A LV12575A (en) 2000-11-20
LV12575B true LV12575B (en) 2001-03-20

Family

ID=23670537

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-60A LV12575B (en) 1989-10-13 2000-05-04 Erythropoietin analogs

Country Status (23)

Country Link
EP (2) EP0668351B1 (cs)
JP (2) JP2983629B2 (cs)
KR (2) KR100221066B1 (cs)
CN (1) CN1063796C (cs)
AT (2) ATE146187T1 (cs)
AU (1) AU646822B2 (cs)
CA (2) CA2165694C (cs)
CZ (4) CZ291515B6 (cs)
DE (2) DE69029370C5 (cs)
DK (2) DK0428267T4 (cs)
ES (2) ES2097753T5 (cs)
FI (1) FI105688B (cs)
GR (2) GR3022658T3 (cs)
HK (1) HK1006718A1 (cs)
IE (1) IE903663A1 (cs)
IL (3) IL95971A0 (cs)
LV (1) LV12575B (cs)
NO (1) NO301832B1 (cs)
NZ (1) NZ235676A (cs)
PT (1) PT95586B (cs)
SK (1) SK284429B6 (cs)
WO (1) WO1991005867A1 (cs)
ZA (1) ZA908166B (cs)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
WO1994024160A2 (en) * 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
IL192290A0 (en) * 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5989538A (en) * 1995-02-15 1999-11-23 Amgen Inc. Mpl ligand analogs
US5696250A (en) 1995-02-15 1997-12-09 Amgen Inc. DNA encoding megakaryocyte growth and development factor analogs
IL128229A0 (en) 1996-08-02 1999-11-30 Ortho Mcneil Pharm Inc Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
IL124015A0 (en) * 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
WO1999054486A1 (en) 1998-04-22 1999-10-28 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
ATE355303T1 (de) * 1998-10-23 2006-03-15 Amgen Inc Methoden und zusammensetzungen zur prävention und behandlung der anämie
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
BR9905868A (pt) * 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
CA2352538A1 (en) * 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
WO2001081405A2 (en) 2000-04-21 2001-11-01 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1382964A4 (en) 2001-04-17 2009-06-10 Chugai Pharmaceutical Co Ltd METHOD FOR TENSID QUANTIFICATION
KR100900166B1 (ko) 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
KR100467750B1 (ko) * 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
DE20321793U1 (de) 2002-09-11 2010-06-02 Fresenius Kabi Deutschland Gmbh Hydroxyalkylstärke-Derivate
MXPA05002594A (es) 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
ES2626268T3 (es) 2002-09-11 2017-07-24 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
ATE409048T1 (de) 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
US8080682B2 (en) 2006-08-24 2011-12-20 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
JP2007517769A (ja) 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
EP1848461A2 (en) 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Conjugates of an epo moiety and a polymer
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1931199A4 (en) 2005-08-31 2009-07-29 Univ Tennessee Res Foundation COMBATING NURSE DISEASE, BURNS, WOUNDS AND BACKMARK INJURIES WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS
EP1957637B1 (en) 2005-12-08 2013-08-14 Amgen, Inc. Improved host cells and culture methods
SI1957630T2 (sl) 2005-12-08 2023-07-31 Amgen Inc. Izboljšana proizvodnja glikoproteinov z uporabo mangana
EP1978030A4 (en) * 2006-01-18 2009-12-30 Chugai Pharmaceutical Co Ltd PROCESS FOR REMOVING SIALIC ACID AND METHOD FOR PRODUCING ASIALOERYTHROPOIETIN
EP1997505A4 (en) 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF A ERYTHROPOETIN SOLUTION
AU2007255717B2 (en) 2006-06-07 2013-07-11 Chugai Seiyaku Kabushiki Kaisha Treatment of ischemic disease using erythropoietin
HUE032274T2 (en) 2006-07-12 2017-09-28 Univ Tennessee Res Found Substituted acetanilides and methods of their application
MX2009000685A (es) 2006-07-21 2009-01-30 Amgen Inc Metodo para detectar y/o cuantificar hepcidina en una muestra.
EP2043692B1 (en) 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
CA2661054A1 (en) 2006-08-22 2008-02-28 Chugai Seiyaku Kabushiki Kaisha Prophylactic and/or therapeutic agents for peripheral neuropathy
EP2081956B1 (en) 2006-11-13 2013-03-20 Charité - Universitätsmedizin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
AR065613A1 (es) 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
AU2009206306B2 (en) 2008-01-25 2013-06-06 Amgen Inc. Ferroportin antibodies and methods of use
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
DE102008002209A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EP2161031A1 (en) 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
EP2334699B1 (en) * 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
EP2349332B1 (en) 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
DE102008054716A1 (de) 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
WO2011011674A2 (en) 2009-07-24 2011-01-27 Dr. Reddy's Laboratories Ltd. Production of erythropoiesis stimulating protein using metal ions
EA022396B1 (ru) 2009-09-23 2015-12-30 Ратиофарм Гмбх Способ очистки рекомбинантного эритропоэтина человека (epo), эритропоэтин, очищенный данным способом, и фармацевтические композиции, содержащие такой эритропоэтин
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
CA3021845C (en) 2011-04-20 2022-03-29 Amgen Inc. Autoinjector apparatus
LT3045187T (lt) 2011-10-14 2019-07-10 Amgen Inc. Injekcijų įrenginys ir surinkimo būdas
US20150065689A1 (en) * 2012-04-10 2015-03-05 Dr. Reddy's Laboratories Limited Single step fractionation method
HUE052574T2 (hu) 2012-07-13 2021-05-28 Oncternal Therapeutics Inc Eljárás mellrákok kezelésére szelektív ösztrogén receptor modulátorral (SARM)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
EP2740805B1 (en) 2012-12-07 2019-02-20 SuppreMol GmbH Stratification and treatment of patients suffering from idiopathic thrombocytopenic purpura
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP2968503B1 (en) 2013-03-15 2018-08-15 Intrinsic LifeSciences LLC Anti-hepcidin antibodies and uses thereof
TWI580451B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
CN105142695B (zh) 2013-03-15 2020-06-02 安进公司 身体轮廓可调适的自动注射器装置
SG11201507878SA (en) 2013-03-22 2015-10-29 Amgen Inc Injector and method of assembly
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3421066B1 (en) 2013-10-24 2021-03-03 Amgen Inc. Injector and method of assembly
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP6640113B2 (ja) 2014-05-07 2020-02-05 アムジエン・インコーポレーテツド 衝撃低減要素を有する自動注入器
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
CN112237662B (zh) 2014-06-03 2022-10-21 安姆根有限公司 药物递送系统和使用方法
WO2016049036A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
EP3455142B1 (en) 2016-05-13 2023-08-09 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
US11369736B2 (en) 2017-02-17 2022-06-28 Amgen Inc. Cannula insertion and retraction mechanisms
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
EP3570871B1 (en) 2017-03-20 2020-11-18 H. Hoffnabb-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
KR102651078B1 (ko) 2017-03-28 2024-03-22 암겐 인코포레이티드 플런저 로드 및 주사기 조립 시스템 및 방법
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MA49677A (fr) 2017-07-25 2021-04-21 Amgen Inc Dispositif d'administration de médicament avec module d'engrenage et procédé d'assemblage associé
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
IL273664B1 (en) 2017-11-06 2026-02-01 Amgen Inc Full-fledged assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
EP3829692A1 (en) 2018-07-31 2021-06-09 Amgen Inc. Fluid path assembly for a drug delivery device
EP3856284A1 (en) 2018-09-24 2021-08-04 Amgen Inc. Interventional dosing systems and methods
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
AU2019359801B2 (en) 2018-10-15 2025-01-02 Amgen Inc. Platform assembly process for drug delivery device
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
ES3010833T3 (en) 2018-11-01 2025-04-04 Amgen Inc Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
AU2020263289B2 (en) 2019-04-24 2025-05-22 Amgen Inc. Syringe sterilization verification assemblies and methods
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
CU24704B1 (es) * 2019-09-05 2024-04-08 Ct Inmunologia Molecular Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
MX2023013640A (es) 2021-05-21 2023-11-30 Amgen Inc Metodo de optimizacion de una receta de llenado para un contenedor de medicamento.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
KR20250099137A (ko) 2022-11-02 2025-07-01 에프. 호프만-라 로슈 아게 당단백질 조성물의 생산 방법
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2354793A1 (fr) * 1976-06-14 1978-01-13 Gresset Bernard Jouet tel que tableau
FR2475988A2 (fr) * 1978-09-04 1981-08-21 Cassagnes Andre Appareil a dessiner
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung

Also Published As

Publication number Publication date
HK1010398A1 (en) 1999-06-17
SK284429B6 (sk) 2005-04-01
IL125175A (en) 2004-07-25
ZA908166B (en) 1991-08-28
IL95971A0 (en) 1991-07-18
CA2027635A1 (en) 1991-04-14
CZ497290A3 (cs) 2000-08-16
NO301832B1 (no) 1997-12-15
IE903663A1 (en) 1991-04-24
AU6604290A (en) 1991-05-16
DK0428267T4 (da) 2005-03-14
CZ291488B6 (cs) 2003-03-12
ATE184914T1 (de) 1999-10-15
DK0668351T3 (da) 1999-12-20
FI912829A0 (fi) 1991-06-12
NO912281L (no) 1991-06-13
EP0428267A2 (en) 1991-05-22
CA2165694A1 (en) 1991-04-14
JPH08151398A (ja) 1996-06-11
EP0428267B2 (en) 2004-12-08
WO1991005867A1 (en) 1991-05-02
DE69029370T2 (de) 1997-06-05
EP0428267A3 (en) 1991-08-14
FI105688B (fi) 2000-09-29
ES2097753T5 (es) 2005-07-01
JP3073905B2 (ja) 2000-08-07
CA2027635C (en) 2001-12-04
AU646822B2 (en) 1994-03-10
CN1063796C (zh) 2001-03-28
PT95586B (pt) 1997-08-29
CZ291471B6 (cs) 2003-03-12
CZ291472B6 (cs) 2003-03-12
CN1051936A (zh) 1991-06-05
GR3022658T3 (en) 1997-05-31
GR3032089T3 (en) 2000-03-31
NO912281D0 (no) 1991-06-13
DE69029370C5 (de) 2010-03-25
DE69029370D1 (de) 1997-01-23
JP2983629B2 (ja) 1999-11-29
KR920701255A (ko) 1992-08-11
EP0428267B1 (en) 1996-12-11
NZ235676A (en) 1992-04-28
EP0668351A1 (en) 1995-08-23
PT95586A (pt) 1991-09-30
KR100263845B1 (ko) 2000-08-16
DE69029370T3 (de) 2006-02-23
ATE146187T1 (de) 1996-12-15
DE69033301T2 (de) 2000-04-20
CZ291515B6 (cs) 2003-03-12
ES2097753T3 (es) 1997-04-16
SK497290A3 (en) 2000-12-11
HK1006718A1 (en) 1999-03-12
LV12575A (en) 2000-11-20
JPH04502331A (ja) 1992-04-23
DK0428267T3 (da) 1997-06-09
KR100221066B1 (ko) 1999-10-01
DE69033301D1 (de) 1999-10-28
EP0668351B1 (en) 1999-09-22
ES2139764T3 (es) 2000-02-16
CA2165694C (en) 2003-03-18
IL125175A0 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
EP0668351B1 (en) Erythropoietin analogs
RU2159814C2 (ru) Аналог эритропоэтина
US5856298A (en) Erythropoietin isoforms
US7217689B1 (en) Glycosylation analogs of erythropoietin
JP3115318B2 (ja) Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
JP3276933B2 (ja) エリスロポエチン活性を有する糖蛋白質の製造方法
JPH01502196A (ja) 炭水化物含量を低下させたコロニー刺激因子
HK1010398B (en) Erythropoietin analogs
IE83805B1 (en) Erythropoietin analogs
FI106563B (fi) Menetelmä ihmisen erytropoietiinin analogien valmistamiseksi ja niitä koodittavat DNA-sekvenssit
US20220220177A1 (en) Modified human erythropoietin
JPH03500481A (ja) ウシ顆粒球マクロファージコロニー刺激因子
HK1001589B (en) Erythropoietin analogs with additional glycosylation sites